nach oben

Critical Care

Erschienen in:

01.08.2006 | Review

Coagulation abnormalities in critically ill patients

verfasst von: Marcel Levi, Steven M Opal

Erschienen in: Critical Care | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Many critically ill patients develop hemostatic abnormalities, ranging from isolated thrombocytopenia or prolonged global clotting tests to complex defects, such as disseminated intravascular coagulation. There are many causes for a deranged coagulation in critically ill patients and each of these underlying disorders may require specific therapeutic or supportive management. In recent years, new insights into the pathogenesis and clinical management of many coagulation defects in critically ill patients have been accumulated and this knowledge is helpful in determining the optimal diagnostic and therapeutic strategy.

Nur mit Berechtigung zugänglich

Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D, Frans E, Wilmer A, Bobbaers H: Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28: 1871-1876. 10.1097/00003246-200006000-00031CrossRefPubMed

Baughman RP, Lower EE, Flessa HC, Tollerud DJ: Thrombocytopenia in the intensive care unit. Chest 1993, 104: 1243-1247.CrossRefPubMed

Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG: Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30: 1765-1771. 10.1097/00003246-200208000-00015CrossRefPubMed

Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A: Thrombocytopenia in a surgical ICU. Chest 1999, 115: 1363-1370. 10.1378/chest.115.5.1363CrossRefPubMed

Hanes SD, Quarles DA, Boucher BA: Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997, 31: 285-289.PubMed

Akca S, Haji Michael P, de Medonca A, Suter PM, Levi M, Vincent JL: The time course of platelet counts in critically ill patients. Crit Care Med 2002, 30: 753-756. 10.1097/00003246-200204000-00005CrossRefPubMed

Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL: Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999, 25: 63-67. 10.1007/s001340050788CrossRefPubMed

Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ: The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996, 93: 460-463. 10.1046/j.1365-2141.1996.5101050.xCrossRefPubMed

MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M: Early coagulopathy predicts mortality in trauma. J Trauma 2003, 55: 39-44.CrossRefPubMed

10.

Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS: D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002, 121: 1262-1268. 10.1378/chest.121.4.1262CrossRefPubMed

11.

Owings JT, Gosselin RC, Anderson JT, Battistella FD, Bagley M, Larkin EC: Practical utility of the D-dimer assay for excluding thromboembolism in severely injured trauma patients. J Trauma 2001, 51: 425-429.CrossRefPubMed

12.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed

13.

Gando S, Nanzaki S, Sasaki S, Kemmotsu O: Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998, 79: 1111-1115.PubMed

14.

Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S: Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000, 28: 451-457. 10.1097/00003246-200002000-00027CrossRefPubMed

15.

Folman CC, Linthorst GE, van Mourik J, van Willigen G, de Jonge E, Levi M, de Haas M, dem Borne AE: Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost 2000, 83: 923-930.PubMed

16.

Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H: Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997, 103: 114-120. 10.1016/S0002-9343(97)00136-8CrossRefPubMed

17.

Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999, 341: 586-592. 10.1056/NEJM199908193410807CrossRefPubMed

18.

Moake JL: Thrombotic microangiopathies. N Engl J Med 2002, 347: 589-600. 10.1056/NEJMra020528CrossRefPubMed

19.

Tsai HM: Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003, 23: 388-396. 10.1161/01.ATV.0000058401.34021.D4CrossRefPubMed

20.

Warkentin TE, Aird WC, Rand JH: Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. Hematology (Am Soc Hematol Educ Program) 2003, 497-519.

21.

Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG: Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003, 23: 745-753. 10.1592/phco.23.6.745.32188CrossRefPubMed

22.

Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332: 1330-1335. 10.1056/NEJM199505183322003CrossRefPubMed

23.

Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003, 101: 2955-2959. 10.1182/blood-2002-07-2201CrossRefPubMed

24.

Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121: 535-555. 10.1046/j.1365-2141.2003.04334.xCrossRefPubMed

25.

Cines DB, Bussel JB, McMillan RB, Zehnder JL: Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program) 2004, 390-406.

26.

Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002, 126: 1415-1423.PubMed

27.

Greaves M, Preston FE: Approach to the bleeding patient. In Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Edited by: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Philadelphia: Lippingcott William and Wilkins; 2001:1031-1043.

28.

Kitchen S, Preston FE: Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999, 25: 17-25.CrossRefPubMed

29.

Bailey B, Amre DK, Gaudreault P: Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003, 31: 299-305. 10.1097/00003246-200301000-00048CrossRefPubMed

30.

Bakhtiari K, Meijers JC, de Jonge E, Levi M: Prospective validation of the international society of thrombosis and maemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004, 32: 2416-2421. 10.1097/01.CCM.0000147769.07699.E3CrossRefPubMed

31.

Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999, 340: 207-214. 10.1056/NEJM199901213400307CrossRefPubMed

32.

Levi M, de Jonge E, Meijers J: The diagnosis of disseminated intravascular coagulation. Blood Rev 2002, 16: 217-223. 10.1016/S0268-960X(02)00032-2CrossRefPubMed

33.

Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86: 1327-1330.PubMed

34.

Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2: 1924-1933. 10.1111/j.1538-7836.2004.00955.xCrossRefPubMed

35.

Muntean W: Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 1999, 23: 979-983. 10.1046/j.1525-1594.1999.06451.xCrossRefPubMed

36.

Rodgers RP, Levin J: A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990, 16: 1-20.CrossRefPubMed

37.

Forestier F, Coiffic A, Mouton C, Ekouevi D, Chene G, Janvier G: Platelet function point-of-care tests in post-bypass cardiac surgery: are they relevant? Br J Anaesth 2002, 89: 715-721. 10.1093/bja/aef250CrossRefPubMed

38.

Levi M: Cancer and DIC. Haemostasis 2001,31(Suppl 1):47-48.PubMed

39.

Teufelsbauer H, Proidl S, Havel M, Vukovich T: Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992, 68: 250-252.PubMed

40.

Hirsh J, Heddle N, Kelton JG: Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004, 164: 361-369. 10.1001/archinte.164.4.361CrossRefPubMed

41.

Mannucci PM: Hemostatic drugs. N Engl J Med 1998, 339: 245-253. 10.1056/NEJM199807233390407CrossRefPubMed

42.

Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997, 90: 2515-2521.PubMed

43.

Levi M, Cromheecke ME, de JE, Prins MH, de MB, Briet E, Buller HR: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints [see comments]. Lancet 1999, 354: 1940-1947. 10.1016/S0140-6736(99)01264-7CrossRefPubMed

44.

Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003, 361: 201-205. 10.1016/S0140-6736(03)12268-4CrossRefPubMed

45.

Levi M, Peters M, Buller HR: Efficacy and safety of recombinant factor VIIa for the treatment of severe bleeding: a systematic review. Crit Care Med 2005, 33: 883-890. 10.1097/01.CCM.0000159087.85970.38CrossRefPubMed

46.

Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y: Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005, 59: 8-15.CrossRefPubMed

47.

Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352: 777-785. 10.1056/NEJMoa042991CrossRefPubMed

48.

Roberts HR: Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol 2001, 38: 48-50. 10.1016/S0037-1963(01)90148-9CrossRefPubMed

49.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353: 1332-1341. 10.1056/NEJMoa050935CrossRefPubMed

50.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL: Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003, 7: 155-163. 10.1186/cc2167PubMedCentralCrossRefPubMed

51.

Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286: 1869-1878. 10.1001/jama.286.15.1869CrossRefPubMed

52.

Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4: 90-97. 10.1111/j.1538-7836.2005.01697.xCrossRefPubMed

Titel: Coagulation abnormalities in critically ill patients
verfasst von: Marcel Levi
Steven M Opal
Publikationsdatum: 01.08.2006
Verlag: BioMed Central
Erschienen in: Critical Care / Ausgabe 4/2006
Elektronische ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc4975

Neu im Fachgebiet AINS

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Coagulation abnormalities in critically ill patients

Abstract

Neu im Fachgebiet AINS

Magen-Darm-Blutungen werden präklinisch oft falsch eingeschätzt

Sepsis-Verdacht: Eine Stunde, fünf essenzielle Maßnahmen

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2006

Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials

Measuring extravascular lung water: animals and humans are not the same

Year in review 2005: Critical Care – nephrology

The outcomes of severe sepsis and septic shock in the UK

Bench-to-bedside review: Significance and interpretation of elevated troponin in septic patients

Gingival and plaque decontamination: Can we take a bite out of VAP?

Neu im Fachgebiet AINS

Magen-Darm-Blutungen werden präklinisch oft falsch eingeschätzt

Sepsis-Verdacht: Eine Stunde, fünf essenzielle Maßnahmen

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS